ASMB

Company Overview — What Does ASSEMBLY BIOSCIENCES, INC. Do?

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. ASSEMBLY BIOSCIENCES, INC. (ASMB) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John G. McHutchison and employs approximately 100 people, headquartered in CARMEL, California. With a market capitalization of $467M, ASMB is one of the notable companies in the Healthcare sector.

ASSEMBLY BIOSCIENCES, INC. (ASMB) Stock Rating — Reduce (April 2026)

As of April 2026, ASSEMBLY BIOSCIENCES, INC. receives a Reduce rating with a composite score of 33.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ASMB ranks #2,477 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ASSEMBLY BIOSCIENCES, INC. ranks #311 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ASMB Stock Price and 52-Week Range

ASSEMBLY BIOSCIENCES, INC. (ASMB) currently trades at $28.86. The stock lost $0.99 (3.3%) in the most recent trading session. The 52-week high for ASMB is $39.70, which means the stock is currently trading -27.3% from its annual peak. The 52-week low is $7.75, putting the stock 272.4% above its annual trough. Recent trading volume was 55K shares, suggesting relatively thin trading activity.

Is ASMB Overvalued or Undervalued? — Valuation Analysis

ASSEMBLY BIOSCIENCES, INC. (ASMB) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.19x, versus the sector average of 2.75x. The price-to-sales ratio is 12.34x, compared to 1.66x for the average Healthcare stock.

At current multiples, ASSEMBLY BIOSCIENCES, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ASSEMBLY BIOSCIENCES, INC. Profitability — ROE, Margins, and Quality Score

ASSEMBLY BIOSCIENCES, INC. (ASMB) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -18.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -14.7% versus the sector average of -33.1%.

On a margin basis, ASSEMBLY BIOSCIENCES, INC. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -120.4% (sector: -66.1%). Net profit margin stands at -106.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 26.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ASMB Debt, Balance Sheet, and Financial Health

ASSEMBLY BIOSCIENCES, INC. has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.22x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $23M.

ASMB has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ASSEMBLY BIOSCIENCES, INC. is 44/100, reflecting average volatility within the normal range for its sector.

ASSEMBLY BIOSCIENCES, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ASSEMBLY BIOSCIENCES, INC. reported revenue of $37M and earnings per share (EPS) of $-0.55. Net income for the quarter was $-38M. Gross margin was 100.0%. Operating income came in at $-43M.

In FY 2025, ASSEMBLY BIOSCIENCES, INC. reported revenue of $72M and earnings per share (EPS) of $-0.55. Net income for the quarter was $-6M. Revenue grew 153.5% year-over-year compared to FY 2024. Operating income came in at $-12M.

In Q3 2025, ASSEMBLY BIOSCIENCES, INC. reported revenue of $11M and earnings per share (EPS) of $-0.72. Net income for the quarter was $-9M. Revenue grew 57.6% year-over-year compared to Q3 2024. Operating income came in at $-11M.

In Q2 2025, ASSEMBLY BIOSCIENCES, INC. reported revenue of $10M and earnings per share (EPS) of $-1.33. Net income for the quarter was $-10M. Revenue grew 12.8% year-over-year compared to Q2 2024. Operating income came in at $-11M.

Over the past 8 quarters, ASSEMBLY BIOSCIENCES, INC. has demonstrated a growth trajectory, with revenue expanding from $9M to $37M. Investors analyzing ASMB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ASMB Dividend Yield and Income Analysis

ASSEMBLY BIOSCIENCES, INC. (ASMB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ASMB Momentum and Technical Analysis Profile

ASSEMBLY BIOSCIENCES, INC. (ASMB) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ASMB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ASSEMBLY BIOSCIENCES, INC. (ASMB) ranks #311 out of 838 stocks based on the Blank Capital composite score. This places ASMB in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ASMB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ASMB vs S&P 500 (SPY) comparison to assess how ASSEMBLY BIOSCIENCES, INC. stacks up against the broader market across all factor dimensions.

ASMB Next Earnings Date

No upcoming earnings date has been announced for ASSEMBLY BIOSCIENCES, INC. (ASMB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ASMB? — Investment Thesis Summary

The quantitative profile for ASSEMBLY BIOSCIENCES, INC. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers.

In summary, ASSEMBLY BIOSCIENCES, INC. (ASMB) earns a Reduce rating with a composite score of 33.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ASMB stock.

Related Resources for ASMB Investors

Explore more research and tools: ASMB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ASMB head-to-head with peers: ASMB vs AZN, ASMB vs SLGL, ASMB vs VMD.